BioSpace News Archive

Bryn Pharma, LLC (“Bryn” or the “Company”), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced that a series of preclinical stud

Medigate, a dedicated medical device security and asset management solution firm, today announced the Medigate Healthcare Protection Solution powered by Dell Technologies.

ALASTIN Skincare®, Inc. - a specialty aesthetics company dedicated to developing and marketing innovative, clinically-tested physician-dispensed skin care products, is pleased to announce the publication of a clinical study highlighting their most recent award-winning breakthrough product, INhance Post-Injection Serum with TriHex Technology®.

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the pricing of its previously announced public offering for the offering of 2,175,000 shares of common stock of the Company at a price to the public of $11.40 per share

RTI Surgical Holdings, Inc., a global surgical implant company, announced two senior leadership appointments to support its transition to a pure-play global spine company.

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it will host a Key Opinion Leader (KOL) call on clinical outcome assessments (COAs) on Tuesday, June 16th at 8:00 am Eastern Time.

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $629,217 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop an Enzyme-Lin

- Rilonacept pivotal Phase 3 data in recurrent pericarditis expected in Q3 2020 - - Mavrilimumab Phase 2 data in GCA and KPL-404 Phase 1 data expected in Q4 2020 - - Management to provide a corporate update at the 41 st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11 th at 3pm EDT - HAMILTON, Bermuda, June 10, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, deve

The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of its first milestone and milestone payment by Autotelic BIO. OT-101 and IL-2 demonstrated good synergy against tumor xenograft model as an immune-oncology therapy. OT-101/IL-2 combination will advance to Phase 1 clinical development. AGOURA HILLS, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Mateo

IntelGenx Corp. announced that Health Canada has authorized the sale of IntelGenx’s hand sanitizer product, both in liquid and gel formulations, which will be manufactured using excess capacity at the Company’s Health Canada-certified cGMP manufacturing facility in Montreal.